Lawmakers demand information on Mylan’s EpiPen price increase
Members of Congress, including U.S. Rep. Tim Murphy, are demanding more information on why the price for lifesaving EpiPens skyrocketed.
EpiPens are injection devices used to ward off potentially fatal allergic reactions, and the price surged in recent years. A two-dose package cost about $94 nine years ago. The average cost was more than six times that in May, according to Elsevier Clinical Solutions’ Gold Standard Drug Database.
Sen. Charles Grassley, R-Iowa, wrote Southpointe-based Mylan N.V., the company that manufactures the devices, and asked for more information on why the prices increased. He cited the cost to parents whose children need them and also to schools that keep the EpiPens on hand. He noted the costs can also be passed on to taxpayers when children are covered by Medicaid or other government programs.
Two other senators, Democrats Mark Warner of Virginia and Richard Blumenthal of Connecticut, also wrote the company about the high prices. Warner said in a letter Tuesday the issue is personal for him.
“As the parent of a child with severe allergies, I am all too familiar with the life-or-death importance of these devices,” Warner wrote.
Rep. Grace Meng, D-N.Y., on Tuesday asked the House Oversight and Government Reform Committee to hold a hearing on the issue. She is a co-chair of the Congressional Kids Safety Caucus.
“Thousands of Americans rely on EpiPens in a given year, and perhaps no time is more important in the purchasing of these devices than the beginning of a new school year,” Meng wrote in a letter to committee chairman Jason Chaffetz, R-Utah, and top Democrat Elijah Cummings of Maryland.
Those requests were followed Wednesday by Murphy, R-18th District, who holds a senior position on the House Energy and Commerce Committee as chairman of Oversight and Investigations, which has jurisdiction over the U.S. Food and Drug Administration.
Murphy said he talked with Mylan Wednesday and asked the company for “all of the variables that went into” the pricing of the EpiPen.
“We’re taking a deeper dive” into the issue, he said, noting the EpiPen’s status as a life-saving medication.
Murphy, who said his office was also preparing a letter of inquiry to Mylan, said the company was to release additional information today.
A two-dose package of the EpiPen sold for an average $608 in May, according to the Elsevier database, and possibly rose since.
In a statement issued Monday, Mylan said it has savings programs for patients and is also offering free EpiPens to schools. The company said about half of U.S. schools are participating in that program.
Recent changes in health insurance resulted in higher deductible costs for many families, the company said. “This current and ongoing shift has presented new challenges for consumers, and now they are bearing more of the cost” of the devices, the statement said.